Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Oncology Companion Diagnostics Market Revenue Growth Supported By A CAGR Of 6.49% Through 2030
The market for companion diagnostics in oncology has experienced substantial expansion recently, projected to escalate from $3.79 billion in 2025 to $4.29 billion in 2026, reflecting a compound annual growth rate of 13.0%. This upward trajectory in the historical period is underpinned by several key factors including the increasing incidence of cancers like breast, colorectal, and melanoma, a heightened emphasis on individualized treatment approaches, a growing need for precise targeted therapy selection, the proliferation of diagnostic laboratories and healthcare facilities, and advancements in molecular and genetic testing methodologies.
The market for oncology companion diagnostics is poised for substantial expansion over the coming years, projected to reach $6.5 billion by 2030, reflecting a compound annual growth rate of 10.9%. This anticipated surge is fueled by several key factors: the increasing embrace of next-generation sequencing (NGS) and PCR-based diagnostic methods, enhanced partnerships between pharmaceutical and diagnostic firms, a growing number of regulatory approvals for companion diagnostics, a heightened demand for personalized cancer treatments, and a greater utilization of bioinformatics and decision-support software within the diagnostic landscape. Significant trends expected to shape this market during the forecast period include the growing adoption of digital platforms for managing companion diagnostic data, a more pronounced integration of artificial intelligence in analyzing biomarkers and stratifying patient populations, the expanding application of genomics and precision medicine in the development of targeted cancer therapies, increased automation in diagnostic testing and laboratory processes, and the rising use of the Internet of Things (IoT) for monitoring diagnostic equipment and consumables.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15623&type=smp
Oncology Companion Diagnostics Market Growth Factors: Which Forces Are Supporting Market Expansion?
The projected increase in cancer incidence is anticipated to be a primary catalyst for the expansion of the oncology companion diagnostics market. Cancer, characterized by the uncontrolled proliferation and dissemination of aberrant cells within the body, is on the rise due to a confluence of factors including altered lifestyles, environmental influences, the global obesity crisis, tobacco consumption, and hereditary predispositions. Within the realm of oncology, companion diagnostics are instrumental in advancing personalized medicine, transforming patient care by facilitating tailored treatment choices, boosting therapeutic effectiveness, mitigating unwanted side effects, streamlining participation in clinical studies, and improving the oversight of treatment progress. Illustrating this trend, data from the US National Cancer Institute in May 2024 reported approximately 20 million new cancer diagnoses and 9.7 million fatalities linked to the disease in 2022, with projections suggesting an annual toll of 15.3 million deaths and 29.9 million new cases by the year 2040. Consequently, the escalating number of cancer diagnoses directly fuels the growth trajectory of the oncology companion diagnostics market.
Oncology Companion Diagnostics Market Segment Analysis Highlighting Growth Areas
The oncology companion diagnostics market covered in this report is segmented –
1) By Product: Instrument, Consumables, Software
2) By Disease Type: Melanoma, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Other Disease Types
3) By Technology: Immunohistochemistry (IHC), In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH), Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
4) By End User: Hospital, Pathology Or Diagnostic Laboratory, Academic Medical Center, Other End-Users
Subsegments:
1) By Instrument: Polymerase Chain Reaction (PCR) Instruments, Next-Generation Sequencing (NGS) Systems, Immunohistochemistry (IHC) Instruments, Fluorescence In Situ Hybridization (FISH) Instruments, Microarray Platforms
2) By Consumables: Reagents And Kits (DNA Or RNA Extraction Kits, PCR Reagents), Biopsy Needles, Testing Slides And Chips, Control And Calibration Samples
3) By Software: Data Analysis Software, Bioinformatics Software (For Gene Expression Analysis), Companion Diagnostic Decision Support Software, Clinical Workflow Management Software
Oncology Companion Diagnostics Market Industry Trends: What Changes Are Reshaping Demand?
Leading entities within the oncology companion diagnostics sector are prioritizing the advancement of sophisticated, high-volume sequencing methodologies. A prime example is the adoption of the c-MET companion diagnostic assay, which aids in therapeutic decision-making for individuals diagnosed with advanced non-small cell lung cancer. This application serves to bolster precision oncology initiatives and refine the selection of personalized treatment regimens. Specifically, the implementation of the c-MET companion diagnostic assay for guiding therapy in advanced NSCLC involves the utilization of a specialized detection test. This test identifies c-MET genetic variations in patients afflicted with advanced non-small cell lung cancer, thereby empowering healthcare providers to choose suitable treatments, maximize therapeutic effectiveness, and champion precision medicine strategies. To illustrate, in May 2025, NeoGenomics, Inc., a prominent American oncology diagnostics firm, introduced its c-MET CDx Assay. This assay is intended to inform therapeutic choices for patients presenting with advanced Non-Small Cell Lung Cancer (NSCLC). The c-MET CDx Assay functions as a companion diagnostic tool, designed to identify c-MET protein overexpression within tumor samples, thereby yielding swift and precise outcomes that pinpoint patients who could benefit from therapies targeting the MET pathway. This assay is characterized by its exceptional sensitivity and specificity, expedited processing times, consistent testing protocols, and seamless integration into standard clinical procedures, positioning it as an invaluable asset for advancing precision oncology and customizing patient care plans.
Oncology Companion Diagnostics Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the oncology companion diagnostics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, BGI Genomics Co. Ltd., Natera Inc., Myriad Genetics Inc., ARUP Laboratories, NeoGenomics Laboratories Inc., Guardant Health, Ambry Genetics Corporation, Biocartis SA, CENTOGENE N.V., Invivoscribe Inc., Pillar Biosciences Inc.
Access The Complete Oncology Companion Diagnostics Market Report:
Oncology Companion Diagnostics Market Leading Geography: Which Region Generates The Most Revenue?
North Americawas the largest region in the oncology companion diagnostic market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the oncology companion diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model